![David Lamond](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Lamond
Président chez
QUINCE THERAPEUTICS, INC.
Fortune : 25 208 $ au 31/05/2026
Profil
David A. Lamond was the founder of Lamond Capital Partners LLC, founded in 2011, where the title held was President & Chief Executive Officer from 2011 to 2012.
Mr. Lamond was the founder of Miadora, Inc., founded in 1999, where the title held was Vice President in 2000.
Mr. Lamond is also the founder of Lamond Ventures LLC.
Mr. Lamond is currently Chairman at Quince Therapeutics, Inc. since 2022, Director at Tipping Point Community, Director at Windfall Data, Inc. since 2021, Director at Ubuntu Pathways, Director at Inquis Clinical Research Ltd. since 2020, Director at Inquis Medical, Inc., and President at En Pointe LLC since 2016.
Former positions include Chairman at Lucira Health, Inc. from 2020 to 2022, Independent Director at Applied Molecular Transport, Inc. from 2018 to 2023, Director at Novosteo, Inc. in 2022, Director at EG 427 SAS, Director at Arrinex, Inc., Analyst at Aesop Capital Partners LLP in 2001, Analyst at ARTIS Capital Management LP, and Project Manager at Scient Corp.
in 1999.
Education includes an undergraduate degree from Duke University conferred in 1997 and graduate studies at Duke University School of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/06/2026 | 21 920 ( 0,13% ) | 25 208 $ | 31/05/2026 |
Postes actifs de David Lamond
| Sociétés | Poste | Début |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Président | 01/02/2022 |
Tipping Point Community
 Tipping Point Community Miscellaneous Commercial ServicesCommercial Services Provides funds and infrastructure support services to organizations for charitable donations | Directeur/Membre du Conseil | - |
Inquis Medical, Inc.
 Inquis Medical, Inc. Medical SpecialtiesHealth Technology Develops and manufactures venous thromboembolic diseases treatment devices | Directeur/Membre du Conseil | - |
Windfall Data, Inc.
 Windfall Data, Inc. Data Processing ServicesTechnology Services Provides data processing services | Directeur/Membre du Conseil | 01/03/2021 |
Inquis Clinical Research Ltd.
 Inquis Clinical Research Ltd. Miscellaneous Commercial ServicesCommercial Services Provides clinical nutrition research services | Directeur/Membre du Conseil | 01/02/2020 |
Ubuntu Pathways | Directeur/Membre du Conseil | - |
En Pointe LLC
 En Pointe LLC Financial ConglomeratesFinance Functions as an investment holding company | President | 01/04/2016 |
Anciens postes connus de David Lamond
| Sociétés | Poste | Fin |
|---|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Directeur/Membre du Conseil | 04/06/2023 |
| LUCIRA HEALTH, INC. | Président | 20/10/2022 |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de David Lamond
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
83
Relations au 1er degré
19
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 19 |
|---|---|
Aesop Capital Partners LLP | Finance |
ARTIS Capital Management LP
 ARTIS Capital Management LP Investment ManagersFinance ARTIS Capital Management's investment objective is to provide investors with superior absolute risk-adjusted returns primarily through the purchase and sale of securities of companies that deliver or apply emerging technologies. Stock selection is diversified across numerous technology sub-sectors and trends. Their investment process is opportunistic and driven by intensive independent fundamental analysis, both bottom-up and top-down. The firm's top-down analysis seeks to identify themes/trends such as structural changes, new product cycles, disruptive technologies, capacity issues, pricing power and trends, barriers to entry, macroeconomic issues and demographic changes. In their bottom-up approach, they look to identify quality of business models, management and earnings, intrinsic valuation analysis, expectation quantification, catalysts, sentiment and technical factors. ARTIS takes long positions in companies that exhibit a strong, experienced management team, improving visibility, accelerating earnings and revenue growth, competitive advantage, new product cycle, pricing power, hidden assets, contrarian bias, insider accumulation, clear catalysts and excellent risk/reward ratio. Their short positions are taken in companies that have characteristics such as deteriorating quality of earnings, aggressive accounting practices, potential for outright fraud, increasing competition/capacity issues, eroding market share position, decelerating earnings and revenue growth, persistent and heavy insider selling, inexperienced and overly promotional management, management turnover, unrealistic market expectations, clear catalysts and excellent risk/reward ratio. | Finance |
Lamond Capital Partners LLC
 Lamond Capital Partners LLC Investment ManagersFinance Lamond Capital Partners seeks to invest primarily, but not exclusively, in the publicly-traded equity securities of technology-related issuers. Their funds seek to achieve their investment objective by constructing a portfolio of long and short positions in the stocks of primarily US-listed companies. The funds also invest in the stocks of non-US listed companies. These non-US investments may include securities in companies located in emerging markets. In addition, derivative instruments, such as options, forward contracts and swaps, may be used to attempt to hedge long and short stock positions, as well as for investment purposes. The funds do employ leverage and may engage in a wide variety of transactions designed to enhance return and lower risk, such as securities lending and repurchase agreements. On occasion, the funds may invest in cash and money market debt securities. | Finance |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Miadora, Inc.
 Miadora, Inc. Catalog/Specialty DistributionRetail Trade Retails luxury jewelry on-line | Retail Trade |
Scient Corp.
 Scient Corp. Information Technology ServicesTechnology Services Provides its clients with a comprehensive suite of internet and technology consulting services. | Technology Services |
Tipping Point Community
Tipping Point Community Miscellaneous Commercial ServicesCommercial Services Provides funds and infrastructure support services to organizations for charitable donations | Commercial Services |
Duke University School of Law
 Duke University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quince Therapeutics, Inc.
 Quince Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders and Alzheimer’s diseases | Health Technology |
Lucira Health, Inc.
 Lucira Health, Inc. Medical SpecialtiesHealth Technology Engages in the development and commercialization of disease test kits | Health Technology |
Arrinex, Inc.
 Arrinex, Inc. Medical SpecialtiesHealth Technology Develops and manufactures medical device | Health Technology |
Applied Molecular Transport, Inc.
 Applied Molecular Transport, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biopharmaceutical company that designs and develops novel oral biologic products | Commercial Services |
En Pointe LLC
En Pointe LLC Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Windfall Data, Inc.
Windfall Data, Inc. Data Processing ServicesTechnology Services Provides data processing services | Technology Services |
Ubuntu Pathways | |
Novosteo, Inc.
 Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Develops drug to reduce complications from a broken bone due to a fall | Health Technology |
Inquis Clinical Research Ltd.
Inquis Clinical Research Ltd. Miscellaneous Commercial ServicesCommercial Services Provides clinical nutrition research services | Commercial Services |
Genelpis SAS
 Genelpis SAS BiotechnologyHealth Technology Operates as a biotechnology company that develops pinpoint DNA medicines for chronic diseases | Health Technology |
Inquis Medical, Inc.
Inquis Medical, Inc. Medical SpecialtiesHealth Technology Develops and manufactures venous thromboembolic diseases treatment devices | Health Technology |
Choisissez Zonebourse 
